Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Our approach centers on advancing our innovative pipeline with multiple late-stage clinical programs targeting rare diseases with significant unmet medical needs. In September 2024, the U.S. Food and Drug Administration ("FDA") granted full approval to our lead development program, FILSPARI (sparsentan), which is indicated to slow kidney function decline in adults with primary Immunoglobulin A nephropathy ("IgAN") who are at risk of disease progression.
In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR
Business segments
Q1 2026 · $127.2MThe company’s own SEC segment disclosure.
- FILSPARI$105.2M83%
- Tiopronin Products$19.3M15%
- License$2.7M2%
Travere Therapeutics, Inc. (TVTX) reported revenue of $170M in Q2 2026 (quarter ended June 30, 2026), up 48% from the same quarter a year earlier. That came with a gross margin of 99% and net loss of $35M. For the full year FY2025, revenue was $491M (+110% year on year) and net income −$26M. Its largest product in 2026-Q1 was FILSPARI at $105M, 83% of the disclosed total, just ahead of Tiopronin Products at 15%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.